<code id='6ED54DB241'></code><style id='6ED54DB241'></style>
    • <acronym id='6ED54DB241'></acronym>
      <center id='6ED54DB241'><center id='6ED54DB241'><tfoot id='6ED54DB241'></tfoot></center><abbr id='6ED54DB241'><dir id='6ED54DB241'><tfoot id='6ED54DB241'></tfoot><noframes id='6ED54DB241'>

    • <optgroup id='6ED54DB241'><strike id='6ED54DB241'><sup id='6ED54DB241'></sup></strike><code id='6ED54DB241'></code></optgroup>
        1. <b id='6ED54DB241'><label id='6ED54DB241'><select id='6ED54DB241'><dt id='6ED54DB241'><span id='6ED54DB241'></span></dt></select></label></b><u id='6ED54DB241'></u>
          <i id='6ED54DB241'><strike id='6ED54DB241'><tt id='6ED54DB241'><pre id='6ED54DB241'></pre></tt></strike></i>

          hotspot

          hotspot

          author:entertainment    Page View:65

          Are biotech’s dog days over? What’s a PIPE? And what can unseat Wegovy?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We dive into the the latest craze in the world of biotech finance, involving hedge funds and some insider information, and explain why not everyone thinks it’s such a good idea. We also discuss a banner month for biotech stocks and the latest twist in obesity research.

          advertisement

          For more on what we cover, here’s more on PIPEs; here’s the news from Viking Therapeutics; here’s the latest in MASH; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          focus

          United colonoscopy coverage change 'may cost lives,' doctors say
          United colonoscopy coverage change 'may cost lives,' doctors say

          AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

          read more
          Annovis Bio delivers candor, but not confidence, on Parkinson’s study
          Annovis Bio delivers candor, but not confidence, on Parkinson’s study

          MollyFerguson/STATAnnovisBiohadmybiotechbull%^&!meterrunningredafteritmadealatechangetothedesign

          read more
          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more

          Readout Newsletter: Bristol, Sangamo, Gilead, and more

          EricRisberg/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsl